Coronavirus disease 2019

From LIMSWiki
(Redirected from COVID-19)
Jump to: navigation, search

Coronavirus disease 2019 (COVID-19)
Other names
  • Coronavirus
  • Corona
  • COVID
  • 2019-nCoV acute respiratory disease
  • Novel coronavirus pneumonia[1][2]
  • Severe pneumonia with novel pathogens[3]
Symptoms of coronavirus disease 2019 4.0.svg
Symptoms of COVID-19
Pronunciation
SpecialtyInfectious disease
SymptomsFever, cough, fatigue, shortness of breath, loss of smell; sometimes no symptoms at all[5][6]
ComplicationsPneumonia, viral sepsis, acute respiratory distress syndrome, kidney failure, cytokine release syndrome
Usual onset2–14 days (typically 5) from infection
CausesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Risk factorsTravel, viral exposure
Diagnostic methodrRT-PCR testing, CT scan
PreventionHand washing, face coverings, quarantine, social distancing[7]
TreatmentSymptomatic and supportive
Frequency6,271,577[8] confirmed cases
Deaths375,656 (6.0% of confirmed cases)[8]

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[9] It was first identified in December 2019 in Wuhan, China, and since spread globally, resulting in an ongoing pandemic.[10][11] The first case may be traced back to 17 November 2019.[12] As of 2 June 2020, more than 6.27 million cases have been reported across 188 countries and territories, resulting in more than 375,000 deaths. More than 2.69 million people have recovered.[8]

Common symptoms include fever, cough, fatigue, shortness of breath, and loss of smell and taste.[5][6][13] While the majority of cases result in mild symptoms, some progress to acute respiratory distress syndrome (ARDS) likely precipitated by a cytokine storm,[citation needed] multi-organ failure, septic shock, and blood clots.[14][15][16] The time from exposure to onset of symptoms is typically around five days but may range from two to fourteen days.[5][17]

The virus is primarily spread between people during close contact,[a] most often via small droplets produced by coughing,[b] sneezing, and talking.[6][18][20] The droplets usually fall to the ground or onto surfaces rather than travelling through air over long distances.[6] Less commonly, people may become infected by touching a contaminated surface and then touching their face.[6][18] It is most contagious during the first three days after the onset of symptoms, although spread is possible before symptoms appear, and from people who do not show symptoms.[6][18] The standard method of diagnosis is by real-time reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab.[21] Chest CT imaging may also be helpful for diagnosis in individuals where there is a high suspicion of infection based on symptoms and risk factors; however, guidelines do not recommend using CT imaging for routine screening.[22][23]

Recommended measures to prevent infection include frequent hand washing, maintaining physical distance from others (especially from those with symptoms), quarantine (especially for those with symptoms), covering coughs, and keeping unwashed hands away from the face.[7][24][25] The use of cloth face coverings such as a scarf or a bandana is recommended in public settings to minimise the risk of transmissions, with some authorities requiring their use.[26][27] Medical grade facemasks such as N95 masks should only be used by healthcare workers, first responders and those who care for infected individuals.[28][29]

According to the World Health Organization (WHO), there are no vaccines nor specific antiviral treatments for COVID-19.[6] On 1 May 2020, the United States gave emergency use authorization to the antiviral remdesivir for people hospitalized with severe COVID‑19[citation needed] Management involves the treatment of symptoms, supportive care, isolation, and experimental measures.[30] The World Health Organization (WHO) declared the COVID‑19 outbreak a public health emergency of international concern (PHEIC)[31][32] on 30 January 2020 and a pandemic on 11 March 2020.[11] Local transmission of the disease has occurred in most countries across all six WHO regions.[33]

Video summary (script)

Signs and symptoms

Symptoms of COVID-19[citation needed]
Symptom Range
Fever 83–99%
Cough 59–82%
Loss of appetite 40–84%
Fatigue 44–70%
Shortness of breath 31–40%
Coughing up sputum 28–33%
Muscle aches and pains 11–35%

Fever is the most common symptom, but it is highly variable in severity and presentation, with some older, immunocompromised, or critically ill people not having fever at all.[34][35] In one study, only 44% of people had fever when they presented to the hospital, while 89% went on to develop fever at some point during their hospitalization.[citation needed] A lack of fever does not verify someone is disease free.

Other common symptoms include cough, loss of appetite, fatigue, shortness of breath, sputum production, and muscle and joint pains.[1][5][36] Symptoms such as nausea, vomiting, and diarrhoea have been observed in varying percentages.[37][38][39] Less common symptoms include sneezing, runny nose, sore throat, and skin lesions.[40] Some cases in China initially presented with only chest tightness and palpitations.[41] A decreased sense of smell or disturbances in taste may occur.[42][43] Loss of smell was a presenting symptom in 30% of confirmed cases in South Korea.[13][44]

As is common with infections, there is a delay between the moment a person is first infected and the time he or she develops symptoms. This is called the incubation period. The average incubation period for COVID‑19 is five to six days but commonly ranges from one to 14 days,[6][45] with approximately 10% of cases exceeding that time.[46][47][48]

A minority of cases do not develop noticeable symptoms at any point in time.[citation needed][49] These asymptomatic carriers tend not to get tested, and their role in transmission is not yet fully known.[50][51] However, preliminary evidence suggests they may contribute to the spread of the disease.[52]

Complications

Complications may include pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, septic shock, and death.[10][14][53][54] Cardiovascular complications may include heart failure, arrhythmias, heart inflammation, and blood clots.[55] Approximately 20-30% of people who present with COVID‑19 have elevated liver enzymes reflecting liver injury.[56][57] Neurologic manifestations include seizure, stroke, encephalitis, and Guillain–Barré syndrome (which includes loss of motor functions).[58] Following the infection, children may develop paediatric multisystem inflammatory syndrome, which has symptoms similar to Kawasaki disease, which can be fatal.[59][60]

Cause

Transmission

Cough/sneeze droplets visualised in dark background using Tyndall scattering
Respiratory droplets produced when a man sneezes, visualised using Tyndall scattering
A video discussing the basic reproduction number and case fatality rate in the context of the pandemic (10:19 min)

COVID-19 spreads primarily when people are in close contact and one person inhales small droplets produced by an infected person (symptomatic or not) coughing, sneezing, or talking.[20] WHO recommends 1 metre (3 ft) of social distance;[6] the U.S. CDC recommends 2 metres (6 ft).[18] People can transmit the virus without showing symptoms, but it is unclear how often this happens.[6][18][20] One estimate of the number of those infected who are asymptomatic is 40%.[61]

People are most infectious when they show symptoms (even mild or non-specific symptoms), but may be infectious for up to two days before symptoms appear (pre-symptomatic transmission).[20] They remain infectious an estimated seven to twelve days in moderate cases and an average of two weeks in severe cases.[20]

When the contaminated droplets fall to floors or surfaces they can, though less commonly, remain infectious if people touch contaminated surfaces and then their eyes, nose or mouth with unwashed hands.[6] On surfaces the amount of active virus decreases over time until it can no longer cause infection,[20] and surfaces are thought not to be the main way the virus spreads.[18] It is unknown what amount of virus on surfaces is required to cause infection via this method, but it can be detected for up to four hours on copper, up to one day on cardboard, and up to three days on plastic (polypropylene) and stainless steel (AISI 304).[20][62][63] Surfaces are easily decontaminated with household disinfectants which kill the virus outside the human body or on the hands.[6] Disinfectants or bleach are not a treatment for COVID‑19, and cause health problems when not used properly, such as when used inside the human body.[64]

Sputum and saliva carry large amounts of virus.[6][18][20][65] Although COVID‑19 is not a sexually transmitted infection, kissing, intimate contact, and faecal-oral routes are suspected to transmit the virus.[66][67] Some medical procedures are aerosol-generating[68] and result in the virus being transmitted more easily than normal.[6][20]

COVID‑19 is a new disease, and many of the details of its spread are still under investigation.[6][18][20] It spreads easily between people—easier than influenza but not as easily as measles.[18] Estimates of the number of people infected by one person with COVID-19 (the R0) have varied widely. The WHO's initial estimates of the R0 were 1.4-2.5 (average 1.95), however a more recent review found the basic R0 (without control measures) to be higher at 3.28 and the median R0 to be 2.79.[69]

Virology

Illustration of SARSr-CoV virion

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus, first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan.[70] All features of the novel SARS-CoV-2 virus occur in related coronaviruses in nature.[71] Outside the human body, the virus is killed by household soap, which bursts its protective bubble.[22]

SARS-CoV-2 is closely related to the original SARS-CoV.[72] It is thought to have an animal (zoonotic) origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus Betacoronavirus, in subgenus Sarbecovirus (lineage B) together with two bat-derived strains. It is 96% identical at the whole genome level to other bat coronavirus samples (BatCov RaTG13).[40] In February 2020, Chinese researchers found that there is only one amino acid difference in the binding domain of the S protein between the coronaviruses from pangolins and those from humans; however, whole-genome comparison to date found that at most 92% of genetic material was shared between pangolin coronavirus and SARS-CoV-2, which is insufficient to prove pangolins to be the intermediate host.[73]

Pathophysiology

The lungs are the organs most affected by COVID‑19 because the virus accesses host cells via the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant in type II alveolar cells of the lungs.[74] The virus uses a special surface glycoprotein called a "spike" (peplomer) to connect to ACE2 and enter the host cell.[75] The density of ACE2 in each tissue correlates with the severity of the disease in that tissue and some have suggested decreasing ACE2 activity might be protective,[76][77][unreliable medical source?] though another view is that increasing ACE2 using angiotensin II receptor blocker medications could be protective.[78] As the alveolar disease progresses, respiratory failure might develop and death may follow.[77][unreliable medical source?]

SARS-CoV-2 may also cause respiratory failure through affecting the brainstem as other coronaviruses have been found to invade the central nervous system (CNS). While virus has been detected in cerebrospinal fluid of autopsies, the exact mechanism by which it invades the CNS remains unclear and may first involve invasion of peripheral nerves given the low levels of ACE2 in the brain.[79][80][unreliable medical source?]

The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium[81] as well as endothelial cells and enterocytes of the small intestine.[82][unreliable medical source?]

The virus can cause acute myocardial injury and chronic damage to the cardiovascular system.[83] An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China,[38] and is more frequent in severe disease.[84][unreliable medical source?] Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart.[83] ACE2 receptors are highly expressed in the heart and are involved in heart function.[83][85] A high incidence of thrombosis (31%) and venous thromboembolism (25%) have been found in ICU patients with COVID‑19 infections and may be related to poor prognosis.[86][unreliable medical source?][87][unreliable medical source?] Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels) are thought to play a significant role in mortality, incidences of clots leading to pulmonary embolisms, and ischaemic events within the brain have been noted as complications leading to death in patients infected with SARS-CoV-2. Infection appears to set off a chain of vasoconstrictive responses within the body, constriction of blood vessels within the pulmonary circulation has also been posited as a mechanism in which oxygenation decreases alongside the presentation of viral pneumonia.[88][better source needed]

Another common cause of death is complications related to the kidneys.[88][better source needed] Early reports show that up to 30% of hospitalized patients in both China and New York have experienced some injury to their kidneys, including some persons with no previous kidney problems.[89]

Autopsies of people who died of COVID‑19 have found diffuse alveolar damage (DAD), and lymphocyte-containing inflammatory infiltrates within the lung.[90][unreliable medical source?]

Immunopathology

Although SARS-COV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, patients with severe COVID‑19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated IL-2, IL-7, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-α (MIP-1α), and tumour necrosis factor-α (TNF-α) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology.[38]

Additionally, people with COVID‑19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin.[91]

Systemic inflammation results in vasodilation, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T-cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in COVID‑19 patients.[citation needed] Lymphocytic infiltrates have also been reported at autopsy.[90][unreliable medical source?]

Diagnosis

Demonstration of a nasopharyngeal swab for COVID-19 testing
CDC rRT-PCR test kit for COVID-19[92]

The WHO has published several testing protocols for the disease.[93] The standard method of testing is real-time reverse transcription polymerase chain reaction (rRT-PCR).[94] The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used.[21][95] Results are generally available within a few hours to two days.[96][97] Blood tests can be used, but these require two blood samples taken two weeks apart, and the results have little immediate value.[98] Chinese scientists were able to isolate a strain of the coronavirus and publish the genetic sequence so laboratories across the world could independently develop polymerase chain reaction (PCR) tests to detect infection by the virus.[10][99][100] As of 4 April 2020, antibody tests (which may detect active infections and whether a person had been infected in the past) were in development, but not yet widely used.[101][102][103] The Chinese experience with testing has shown the accuracy is only 60 to 70%.[104] The FDA in the United States approved the first point-of-care test on 21 March 2020 for use at the end of that month.[105]

Diagnostic guidelines released by Zhongnan Hospital of Wuhan University suggested methods for detecting infections based upon clinical features and epidemiological risk. These involved identifying people who had at least two of the following symptoms in addition to a history of travel to Wuhan or contact with other infected people: fever, imaging features of pneumonia, normal or reduced white blood cell count, or reduced lymphocyte count.[106]

A study asked hospitalised COVID‑19 patients to cough into a sterile container, thus producing a saliva sample, and detected the virus in eleven of twelve patients using RT-PCR. This technique has the potential of being quicker than a swab and involving less risk to health care workers (collection at home or in the car).[65]

Along with laboratory testing, chest CT scans may be helpful to diagnose COVID‑19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening.[22][23] Bilateral multilobar ground-glass opacities with a peripheral, asymmetric, and posterior distribution are common in early infection.[22] Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses.[22][107]

In late 2019, the WHO assigned emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID‑19 without lab-confirmed SARS-CoV-2 infection.[108]

Typical CT imaging findings
CT imaging of rapid progression stage

Pathology

Few data are available about microscopic lesions and the pathophysiology of COVID‑19.[109][110] The main pathological findings at autopsy are:[citation needed]

Prevention

Progressively stronger mitigation efforts to reduce the number of active cases at any given time—"flattening the curve"—allows healthcare services to better manage the same volume of patients.[114][115][116] Likewise, progressively greater increases in healthcare capacity—called raising the line—such as by increasing bed count, personnel, and equipment, helps to meet increased demand.[117]
Mitigation attempts that are inadequate in strictness or duration—such as premature relaxation of distancing rules or stay-at-home orders—can allow a resurgence after the initial surge and mitigation.[115][118]

Preventive measures to reduce the chances of infection include staying at home, avoiding crowded places, keeping distance from others, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands.[119][120][121] The U.S. Centers for Disease Control and Prevention (CDC) recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available.[119] Proper hand hygiene after any cough or sneeze is encouraged.[119] The CDC has recommended cloth face coverings in public settings where other social distancing measures are difficult to maintain, in part to limit transmission by asymptomatic individuals.[122] The U.S. National Institutes of Health guidelines do not recommend any medication for prevention of COVID‑19, before or after exposure to the SARS-CoV-2 virus, outside the setting of a clinical trial.[123]

Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel, and cancelling large public gatherings.[124] Distancing guidelines also include that people stay at least 6 feet (1.8 m) apart.[125] There is no medication known to be effective at preventing COVID‑19.[126] After the implementation of social distancing and stay-at-home orders, many regions have been able to sustain an effective transmission rate ("Rt") of less than one, meaning the disease is in remission in those areas.[127] In a simple model

 
   
     
       ln
       
       (
       
         R
         
           t
         
       
       )
       
       
         R
         
           t
         
       
       
       1
     
   
   {\textstyle \ln(R_{t})\approx R_{t}-1}
 

needs on average over time be kept at or below zero to avoid exponential growth.[citation needed]

As a COVID-19 vaccine is not expected until 2021 at the earliest,[128] a key part of managing COVID‑19 is trying to decrease and delay the epidemic peak, known as "flattening the curve".[115] This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of current cases, and delaying additional cases until effective treatments or a vaccine become available.[115][118]

According to the WHO, the use of masks is recommended only if a person is coughing or sneezing or when one is taking care of someone with a suspected infection.[129] For the European Centre for Disease Prevention and Control (ECDC) face masks "... could be considered especially when visiting busy closed spaces ..." but "... only as a complementary measure ..."[130] The U.S. CDC recommends masks in public places where 6-foot social distancing is difficult to maintain, primarily in case you yourself are asymptomatic and to prevent unknowingly spreading the infection.[131]

Several countries have recommended that healthy individuals wear face masks or cloth face coverings (like scarves or bandanas) at least in certain public settings, including China,[132] Hong Kong,[133] Spain,[134] Italy (Lombardy region),[135] Russia,[136] and the United States.[122]

Those diagnosed with COVID‑19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items.[28][137] The CDC also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose, coughing or sneezing. It further recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available.[119]

For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol or isopropanol. Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis". Glycerol is added as a humectant.[138]

Management

People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs.[139][140][141] The CDC recommends those who suspect they carry the virus wear a simple face mask.[28] Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.[citation needed][142] Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity.[143] Supportive treatments may be useful in those with mild symptoms at the early stage of infection.[144]

The WHO, the Chinese National Health Commission, and the United States' National Institutes of Health have published recommendations for taking care of people who are hospitalised with COVID‑19.[123][145][146] Intensivists and pulmonologists in the U.S. have compiled treatment recommendations from various agencies into a free resource, the IBCC.[147][148]

Prognosis

The severity of diagnosed cases in China
The severity of diagnosed COVID-19 cases in China[149]
Case fatality rates for COVID-19 by age by country.
Case fatality rates by age group:
  China, as of 11 February 2020[150]
  South Korea, as of 20 May 2020[citation needed]
  Spain, as of 18 May 2020[citation needed]
  Italy, as of 14 May 2020[151]
Case fatality rate depending on other health problems
Case fatality rate in China depending on other health problems. Data through 11 February 2020.[150]
Case fatality rate by country and number of cases
The number of deaths vs total cases by country and approximate case fatality rate[152]

The severity of COVID‑19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks.[40]

Children make up a small proportion of reported cases, with about 1% of cases being under 10 years and 4% aged 10–19 years.[20] They are likely to have milder symptoms and a lower chance of severe disease than adults. In those younger than 50 years the risk of death is less than 0.5%, while in those older than 70 it is more than 8%.[153][154][155] Pregnant women may be at higher risk of severe COVID‑19 infection based on data from other similar viruses, like Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), but data for COVID‑19 is lacking.[156][157]

Some studies have found that the neutrophil to lymphocyte ratio (NLR) may be helpful in early screening for severe illness.[158]

Most of those who die of COVID‑19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease.[159] The Istituto Superiore di Sanità reported that out of 8.8% of deaths where medical charts were available, 97% of people had at least one comorbidity with the average person having 2.7 diseases.[160] According to the same report, the median time between the onset of symptoms and death was ten days, with five being spent hospitalised. However, people transferred to an ICU had a median time of seven days between hospitalisation and death.[160] In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days.[161] In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%.[162] In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest.[41] According to March data from the United States, 89% of those hospitalised had preexisting conditions.[163]

The availability of medical resources and the socioeconomics of a region may also affect mortality.[164] Concerns have been raised about long-term sequelae of the disease. The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage.[165] This may also lead to post-intensive care syndrome following recovery.[166]

History

The virus is thought to be natural and has an animal origin,[71] through spillover infection.[167] The actual origin is unknown, but the first known cases of infection happened in China. By December 2019, the spread of infection was almost entirely driven by human-to-human transmission.[150][168] A study of the first 41 cases of confirmed COVID‑19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019.[169][170][171] Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019.[172] Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020.[173][174]

Epidemiology

Several measures are commonly used to quantify mortality.[175] These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health.[176]

The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is 6.0% (375,656/6,271,577) as of 2 June 2020.[8] The number varies by region.[177]

Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease. These statistics are not time-bound and follow a specific population from infection through case resolution. Many academics have attempted to calculate these numbers for specific populations.[178]

Outbreaks have occurred in prisons due to crowding and an inability to enforce adequate social distancing.[179][180] In the United States, the prisoner population is aging and many of them are at high risk for poor outcomes from COVID‑19 due to high rates of coexisting heart and lung disease, and poor access to high-quality healthcare.[179]

Total confirmed cases over time
Total deaths over time
Total confirmed cases of COVID‑19 per million people[181]
Total confirmed deaths due to COVID‑19 per million people[182]

Infection fatality rate

Our World in Data states that, as of 25 March 2020, the infection fatality rate (IFR) cannot be accurately calculated.[183] In February, one research group estimated the IFR at 0.94%, with a confidence interval between 0.37 percent to 2.9 percent.[184] The University of Oxford Centre for Evidence-Based Medicine (CEBM) estimated a global CFR of 0.8 to 9.6 percent (last revised 30 April) and IFR of 0.10 to 0.41 percent (last revised 2 May).[185] According to CEBM, random antibody testing in Germany suggested an IFR of 0.37% (0.12% to 0.87%) there, but there have been concerns about false positives.[185][186][187][188][unreliable medical source?] Firm lower limits of infection fatality rates have been established in a number of locations. As of 7 May, in New York City, with a population of 8.4 million, 14,162 have died from COVID-19 (0.17% of the population).[189] In Bergamo province, 0.57% of the population has died.[190][191][unreliable medical source?] To get a better view on the number of people infected, initial antibody testing has been carried out, but there are no valid scientific reports based on any of them as of yet.[192][193] On 1 May antibody testing in New York suggested an IFR of 0.86%.[194]

Sex differences

The impact of the pandemic and its mortality rate are different for men and women.[195] Mortality is higher in men in studies conducted in China and Italy.[1][196][197] The higher risk for men appears in their 50s, and begins to taper off only at 90.[197] In China, the death rate was 2.8 percent for men and 1.7 percent for women.[197] The exact reasons for this sex-difference are not known, but genetic and behavioural factors could be a reason.[195] Sex-based immunological differences, a lower prevalence of smoking in women, and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.[197] In Europe, of those infected with COVID‑19, 57% were men; of those infected with COVID‑19 who also died, 72% were men.[198] As of April 2020, the U.S. government is not tracking sex-related data of COVID‑19 infections.[199] Research has shown that viral illnesses like Ebola, HIV, influenza, and SARS affect men and women differently.[199] A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus.[200] School closures, lockdowns, and reduced access to healthcare following the COVID-19 pandemic may differentially affect the genders and possibly exaggerate existing gender disparity.[195][201]

Ethnic differences

In the U.S., a greater proportion of deaths due to COVID-19 have occurred among African Americans.[202] Structural factors that prevent African Americans from practicing social distancing include their concentration in crowded substandard housing and in "essential" occupations such as public transit and health care. Greater prevalence of lacking health insurance and care and of underlying conditions such as diabetes, hypertension and heart disease also increase their risk of death.[203] Similar issues affect Native American and Latino communities.[202] According to a U.S health policy non-profit, 34% of American Indian and Alaska Native People (AIAN) non-elderly adults are at risk of serious illness compared to 21% of white non-elderly adults.[204] The source attributes it to disproportionately high rates of many health conditions that may put them at higher risk as well as living conditions like lack of access to clean water.[205] Leaders have called for efforts to research and address the disparities.[206]

Society and culture

Name

During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus",[207][208][209] with the disease sometimes called "Wuhan pneumonia".[210][211] In the past, many diseases have been named after geographical locations, such as the Spanish flu,[212] Middle East Respiratory Syndrome, and Zika virus.[213]

In January 2020, the World Health Organisation recommended 2019-nCov[214] and 2019-nCoV acute respiratory disease[215] as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations (e.g. Wuhan, China), animal species or groups of people in disease and virus names to prevent social stigma.[216][217][218]

The official names COVID‑19 and SARS-CoV-2 were issued by the WHO on 11 February 2020.[219] WHO chief Tedros Adhanom Ghebreyesus explained: CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019).[220] The WHO additionally uses "the COVID‑19 virus" and "the virus responsible for COVID‑19" in public communications.[219] Both the disease and virus are commonly referred to as "coronavirus" in the media and public discourse.

Misinformation

After the initial outbreak of COVID‑19, conspiracy theorists spread misinformation and disinformation regarding the origin, scale, prevention, treatment, and other aspects of the disease, which rapidly spread online.[221][222][223]

Decreased emergency room use

In Austria, 39% fewer persons sought help for cardiac symptoms in the month of March. A study estimated that there were 110 incidents of preventable cardiac death as compared to 86 confirmed deaths from Coronavirus as of 29 March.[224]

A preliminary study in the U.S. found 38% under-utilization of cardiac care units as compared to normal.[225] The head of cardiology at the University of Arizona has stated, "My worry is some of these people are dying at home because they're too scared to go to the hospital."[226] There is also concern that persons with symptoms of stroke and appendicitis are delaying seeking help.[226][227]

Other animals

Humans appear to be capable of spreading the virus to some other animals. A domestic cat in Liège, Belgium, tested positive after it started showing symptoms (diarrhoea, vomiting, shortness of breath) a week later than its owner, who was also positive.[228] Tigers and lions at the Bronx Zoo in New York, United States, tested positive for the virus and showed symptoms of COVID‑19, including a dry cough and loss of appetite.[229] Minks at two farms in the Netherlands also tested positive for COVID-19.[230]

A study on domesticated animals inoculated with the virus found that cats and ferrets appear to be "highly susceptible" to the disease, while dogs appear to be less susceptible, with lower levels of viral replication. The study failed to find evidence of viral replication in pigs, ducks, and chickens.[231]

In March 2020, researchers from the University of Hong Kong have shown that Syrian hamsters could be a model organism for COVID-19 research.[232]

Research

No medication or vaccine is approved to treat the disease.[233] International research on vaccines and medicines in COVID‑19 is underway by government organisations, academic groups, and industry researchers.[234][235] In March, the World Health Organisation initiated the "Solidarity Trial" to assess the treatment effects of four existing antiviral compounds with the most promise of efficacy.[236] The World Health Organization suspended hydroxychloroquine from its global drug trials for COVID-19 treatments on 26 May 2020 due to safety concerns. It had previously enrolled 3,500 patients from 17 countries in the Solidarity Trial.[237] France, Italy and Belgium also banned the use of hydroxychloroquine as a COVID-19 treatment.[238]

There has been a great deal of COVID-19 research, involving accelerated research processes and publishing shortcuts to meet the global demand. To minimise the harm from misinformation, medical professionals and the public are advised to expect rapid changes to available information, and to be attentive to retractions and other updates.[239]

Vaccine

There is no available vaccine, but various agencies are actively developing vaccine candidates. Previous work on SARS-CoV is being used because both SARS-CoV and SARS-CoV-2 use the ACE2 receptor to enter human cells.[240] Three vaccination strategies are being investigated. First, researchers aim to build a whole virus vaccine. The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID‑19. A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus. In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor. A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination). Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.[241]

On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle, Washington, United States. The vaccine contains a harmless genetic code copied from the virus that causes the disease.[242]

Antibody-dependent enhancement has been suggested as a potential challenge for vaccine development for SARS-COV-2, but this is controversial.[243]

Medications

At least 29 phase II–IV efficacy trials in COVID‑19 were concluded in March 2020, or scheduled to provide results in April from hospitals in China.[244][245] There are more than 300 active clinical trials underway as of April 2020.[126] Seven trials were evaluating already approved treatments, including four studies on hydroxychloroquine or chloroquine.[245] Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.[244][245] Other candidates in trials include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2.[245]

The COVID‑19 Clinical Research Coalition has goals to 1) facilitate rapid reviews of clinical trial proposals by ethics committees and national regulatory agencies, 2) fast-track approvals for the candidate therapeutic compounds, 3) ensure standardised and rapid analysis of emerging efficacy and safety data and 4) facilitate sharing of clinical trial outcomes before publication.[246][247]

Several existing medications are being evaluated for the treatment of COVID‑19,[233] including remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and lopinavir/ritonavir combined with interferon beta.[236][248] There is tentative evidence for efficacy by remdesivir, as of March 2020.[249][250] Clinical improvement was observed in patients treated with compassionate-use remdesivir.[251] Remdesivir inhibits SARS-CoV-2 in vitro.[252] Phase III clinical trials are underway in the U.S., China, and Italy.[233][244][253]

In 2020, a trial found that lopinavir/ritonavir was ineffective in the treatment of severe illness.[254] Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.[252]

There are mixed results as of 3 April 2020 as to the effectiveness of hydroxychloroquine as a treatment for COVID‑19, with some studies showing little or no improvement.[255][256] One study has shown an association between hydroxychloroquine or chloroquine use with higher death rates along with other side effects.[257][258] The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.[126]

Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID‑19 treatment.[126]

Cytokine storm

A cytokine storm can be a complication in the later stages of severe COVID‑19. There is preliminary evidence that hydroxychloroquine may be useful in controlling cytokine storms in late-phase severe forms of the disease.[259]

Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.[260][261] It is undergoing a phase 2 non-randomised trial at the national level in Italy after showing positive results in people with severe disease.[262][263] Combined with a serum ferritin blood test to identify a cytokine storm (also called cytokine storm syndrome, not to be confused with cytokine release syndrome), it is meant to counter such developments, which are thought to be the cause of death in some affected people.[264][265][266] The interleukin-6 receptor antagonist was approved by the FDA to undergo a phase III clinical trial assessing the its effectiveness on COVID‑19 based on retrospective case studies for the treatment of steroid-refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.[267] To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS. Prophylactic tocilizumab has been shown to increase serum IL-6 levels by saturating the IL-6R, driving IL-6 across the blood-brain barrier, and exacerbating neurotoxicity while having no effect on the incidence of CRS.[268]

Lenzilumab, an anti-GM-CSF monoclonal antibody, is protective in murine models for CAR T cell-induced CRS and neurotoxicity and is a viable therapeutic option due to the observed increase of pathogenic GM-CSF secreting T-cells in hospitalised patients with COVID‑19.[269]

The Feinstein Institute of Northwell Health announced in March a study on "a human antibody that may prevent the activity" of IL-6.[270]

Passive antibodies

Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID‑19 to people who need them is being investigated as a non-vaccine method of passive immunisation.[271] This strategy was tried for SARS with inconclusive results.[271] Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2.[272] The spike protein of SARS-CoV-2 is the primary target for neutralizing antibodies.[272] Other mechanisms, however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible.[271] Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.[271] Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.[273]

See also

Notes

  1. ^ Close contact is defined as one metre (~3.3 feet) by the WHO[6] and ~1.8 metres (six feet) by the CDC.[18]
  2. ^ An uncovered cough can travel up to 8.2 metres (27 feet).[19]

References

  1. ^ a b c Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. (February 2020). "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". Lancet. 395 (10223): 507–513. doi:10.1016/S0140-6736(20)30211-7. PMC 7135076. PMID 32007143.
  2. ^ Han X, Cao Y, Jiang N, Chen Y, Alwalid O, Zhang X, et al. (March 2020). "Novel Coronavirus Pneumonia (COVID-19) Progression Course in 17 Discharged Patients: Comparison of Clinical and Thin-Section CT Features During Recovery". Clinical Infectious Diseases. doi:10.1093/cid/ciaa271. PMC 7184369. PMID 32227091.
  3. ^ "Special Act for Prevention, Relief and Revitalization Measures for Severe Pneumonia with Novel Pathogens – Article Content – Laws & Regulations Database of The Republic of China". law.moj.gov.tw. Retrieved 10 May 2020.
  4. ^ "Covid-19, n." Oxford English Dictionary. Retrieved 15 April 2020.
  5. ^ a b c d "Symptoms of Coronavirus". U.S. Centers for Disease Control and Prevention (CDC). 20 March 2020. Archived from the original on 30 January 2020.
  6. ^ a b c d e f g h i j k l m n o p "Q&A on coronaviruses (COVID-19)". World Health Organization (WHO). 17 April 2020. Archived from the original on 14 May 2020. Retrieved 14 May 2020.
  7. ^ a b Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, et al. (April 2020). "Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review". The Cochrane Database of Systematic Reviews. 4: CD013574. doi:10.1002/14651858.CD013574. PMC 7141753. PMID 32267544.
  8. ^ a b c d "COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS. Johns Hopkins University. Retrieved 2 June 2020.
  9. ^ "Coronavirus disease 2019 (COVID-19)—Symptoms and causes". Mayo Clinic. Retrieved 14 April 2020.
  10. ^ a b c Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. (February 2020). "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China". International Journal of Infectious Diseases. 91: 264–266. doi:10.1016/j.ijid.2020.01.009. PMC 7128332. PMID 31953166.
  11. ^ a b "WHO Director-General's opening remarks at the media briefing on COVID-19". World Health Organization (WHO) (Press release). 11 March 2020. Archived from the original on 11 March 2020. Retrieved 12 March 2020.
  12. ^ "China's first confirmed Covid-19 case traced back to November 17". South China Morning Post. 13 March 2020. Retrieved 28 May 2020.
  13. ^ a b Hopkins C. "Loss of sense of smell as marker of COVID-19 infection". Ear, Nose and Throat surgery body of United Kingdom. Retrieved 28 March 2020.
  14. ^ a b Murthy S, Gomersall CD, Fowler RA (March 2020). "Care for Critically Ill Patients With COVID-19". JAMA. 323 (15): 1499. doi:10.1001/jama.2020.3633. PMID 32159735.
  15. ^ Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020). "Features, Evaluation and Treatment Coronavirus (COVID-19)". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32150360. Retrieved 18 March 2020.
  16. ^ Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. (April 2020). "COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up". Journal of the American College of Cardiology. doi:10.1016/j.jacc.2020.04.031. PMC 7164881. PMID 32311448.
  17. ^ Velavan TP, Meyer CG (March 2020). "The COVID-19 epidemic". Tropical Medicine & International Health. 25 (3): 278–280. doi:10.1111/tmi.13383. PMC 7169770. PMID 32052514.
  18. ^ a b c d e f g h i j "How COVID-19 Spreads". Centers for Disease Control and Prevention (CDC). 2 April 2020. Archived from the original on 3 April 2020. Retrieved 3 April 2020.
  19. ^ Bourouiba L (March 2020). "Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19". JAMA. doi:10.1001/jama.2020.4756. PMID 32215590.
  20. ^ a b c d e f g h i j k "Q & A on COVID-19". European Centre for Disease Prevention and Control. Retrieved 30 April 2020.
  21. ^ a b "Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 4 March 2020. Retrieved 26 March 2020.
  22. ^ a b c d e Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A (March 2020). "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients". AJR. American Journal of Roentgenology: 1–7. doi:10.2214/AJR.20.23034. PMID 32174129.
  23. ^ a b "ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection". American College of Radiology. 22 March 2020. Archived from the original on 28 March 2020.
  24. ^ "Advice for public". World Health Organization (WHO). Archived from the original on 26 January 2020. Retrieved 25 February 2020.
  25. ^ "Guidance on social distancing for everyone in the UK". GOV.UK. Archived from the original on 24 March 2020. Retrieved 25 March 2020.
  26. ^ CDC (11 February 2020). "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". Centers for Disease Control and Prevention. Retrieved 31 May 2020.
  27. ^ Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ (May 2020). "Rational use of face masks in the COVID-19 pandemic". The Lancet. Respiratory Medicine. 8 (5): 434–436. doi:10.1016/S2213-2600(20)30134-X. PMC 7118603. PMID 32203710.
  28. ^ a b c Centers for Disease Control and Prevention (5 April 2020). "What to Do if You Are Sick". Centers for Disease Control and Prevention (CDC). Archived from the original on 14 February 2020. Retrieved 24 April 2020.
  29. ^ "When and how to use masks". World Health Organization (WHO). Archived from the original on 7 March 2020. Retrieved 24 April 2020.
  30. ^ "How to Protect Yourself & Others". Centers for Disease Control and Prevention (CDC). 8 April 2020. Archived from the original on 26 February 2020. Retrieved 9 April 2020.
  31. ^ "Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)". World Health Organization (WHO). Archived from the original on 31 January 2020. Retrieved 11 February 2020.
  32. ^ Mahtani S, Berger M, O'Grady S, Iati M (6 February 2020). "Hundreds of evacuees to be held on bases in California; Hong Kong and Taiwan restrict travel from mainland China". The Washington Post. Archived from the original on 7 February 2020. Retrieved 11 February 2020.
  33. ^ "WHO Situation Report #87" (PDF). World Health Organization (WHO). 16 April 2020.
  34. ^ Chavez, Summer; Long, Brit; Koyfman, Alex; Liang, Stephen Y. (30 January 2020). "Coronavirus Disease (COVID-19): A primer for emergency physicians". The American Journal of Emergency Medicine. doi:10.1016/j.ajem.2020.03.036. PMC 7102516. PMID 32265065.
  35. ^ Tu, Huilan; Tu, Sheng; Gao, Shiqi; Shao, Anwen; Sheng, Jifang (26 March 2020). "The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event". The Journal of Infection. doi:10.1016/j.jinf.2020.04.011. PMC 7166041. PMID 32315723.
  36. ^ Hessen MT (27 January 2020). "Novel Coronavirus Information Center: Expert guidance and commentary". Elsevier Connect. Archived from the original on 30 January 2020. Retrieved 31 January 2020.
  37. ^ Wei XS, Wang X, Niu YR, Ye LL, Peng WB, Wang ZH, et al. (26 February 2020). "Clinical Characteristics of SARS-CoV-2 Infected Pneumonia with Diarrhea". doi:10.2139/ssrn.3546120.
  38. ^ a b c Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (February 2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet. 395 (10223): 497–506. doi:10.1016/S0140-6736(20)30183-5. PMC 7159299. PMID 31986264.
  39. ^ Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR (March 2020). "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges". International Journal of Antimicrobial Agents. 55 (3): 105924. doi:10.1016/j.ijantimicag.2020.105924. PMC 7127800. PMID 32081636.
  40. ^ a b c Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (PDF) (Report). World Health Organization (WHO). 16–24 February 2020. Archived (PDF) from the original on 29 February 2020. Retrieved 21 March 2020.
  41. ^ a b Zheng YY, Ma YT, Zhang JY, Xie X (May 2020). "COVID-19 and the cardiovascular system". Nature Reviews. Cardiology. 17 (5): 259–260. doi:10.1038/s41569-020-0360-5. PMC 7095524. PMID 32139904.
  42. ^ Xydakis MS, Dehgani-Mobaraki P, Holbrook EH, Geisthoff UW, Bauer C, Hautefort C, et al. (April 2020). "Smell and taste dysfunction in patients with COVID-19". The Lancet. Infectious Diseases. doi:10.1016/S1473-3099(20)30293-0. PMC 7159875. PMID 32304629.
  43. ^ "Symptoms of Coronavirus". Centers for Disease Control and Prevention (CDC). 27 April 2020. Retrieved 28 April 2020.
  44. ^ Iacobucci G (March 2020). "Sixty seconds on . . . anosmia". BMJ. 368: m1202. doi:10.1136/bmj.m1202. PMID 32209546.
  45. ^ World Health Organization (19 February 2020). "Coronavirus disease 2019 (COVID-19): situation report, 29". World Health Organization (WHO). hdl:10665/331118.
  46. ^ Rapid Expert Consultation Update on SARS-CoV-2 Surface Stability and Incubation for the COVID-19 Pandemic. TheNational Academies Press. 27 March 2020. doi:10.17226/25763. ISBN 978-0-309-67610-6. Retrieved 18 May 2020.
  47. ^ "Interim Guidance: Public Health Management of cases and contacts associated with novel coronavirus (COVID-19) in the community" (PDF). BC Centre for Disease Control. 15 May 2020. Retrieved 18 May 2020.
  48. ^ "Rapid Review of the literature: Assessing the infection prevention and control measures for the prevention and management of COVID-19 in health and care settings" (PDF). NHS Scotland. 20 April 2020. Retrieved 18 May 2020.
  49. ^ Mizumoto K, Kagaya K, Zarebski A, Chowell G (March 2020). "Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020" (PDF). Euro Surveillance. 25 (10). doi:10.2807/1560-7917.ES.2020.25.10.2000180. PMC 7078829. PMID 32183930.
  50. ^ "Clinical Questions about COVID-19: Questions and Answers". Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 14 February 2020. Retrieved 31 March 2020.
  51. ^ Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. (March 2020). "Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths". Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi. doi:10.1016/j.jmii.2020.02.012. PMC 7128959. PMID 32173241.
  52. ^ Furukawa NW, Brooks JT, Sobel J (2020). "Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic". Emerg Infect Dis. 26 (7). doi:10.3201/eid2607.201595. PMID 32364890.CS1 maint: multiple names: authors list (link)
  53. ^ Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020). "Features, Evaluation and Treatment Coronavirus (COVID-19)". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32150360. Retrieved 18 March 2020.
  54. ^ Heymann DL, Shindo N, et al. (WHO Scientific and Technical Advisory Group for Infectious Hazards) (February 2020). "COVID-19: what is next for public health?". Lancet. Elsevier BV. 395 (10224): 542–545. doi:10.1016/s0140-6736(20)30374-3. PMC 7138015. PMID 32061313.
  55. ^ Long B, Brady WJ, Koyfman A, Gottlieb M (April 2020). "Cardiovascular complications in COVID-19". The American Journal of Emergency Medicine. doi:10.1016/j.ajem.2020.04.048. PMC 7165109. PMID 32317203.
  56. ^ Xu L, Liu J, Lu M, Yang D, Zheng X (May 2020). "Liver injury during highly pathogenic human coronavirus infections". Liver International. 40 (5): 998–1004. doi:10.1111/liv.14435. PMC 7228361. PMID 32170806.
  57. ^ Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (April 2020). "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review". JAMA. doi:10.1001/jama.2020.6019. PMID 32282022.
  58. ^ Carod-Artal FJ (May 2020). "Neurological complications of coronavirus and COVID-19". Revista de Neurologia. 70 (9): 311–322. doi:10.33588/rn.7009.2020179. PMID 32329044.
  59. ^ "Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19". www.who.int. Retrieved 20 May 2020.
  60. ^ "HAN Archive - 00432 | Health Alert Network (HAN)". emergency.cdc.gov. 15 May 2020. Retrieved 20 May 2020.
  61. ^ "Getting a handle on asymptomatic SARS-CoV-2 infection | Scripps Research". www.scripps.edu. Retrieved 16 May 2020.
  62. ^ "New coronavirus stable for hours on surfaces". National Institutes of Health. 17 March 2020. Archived from the original on 23 March 2020. Retrieved 30 April 2020.
  63. ^ van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. (April 2020). "Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1". The New England Journal of Medicine. 382 (16): 1564–1567. doi:10.1056/NEJMc2004973. PMC 7121658. PMID 32182409.
  64. ^ "Household cleaners and disinfectants can cause health problems when not used properly". Centers for Disease Control and Prevention (CDC). 24 April 2020. Retrieved 6 May 2020.
  65. ^ a b To KK, Tsang OT, Chik-Yan Yip C, Chan KH, Wu TC, Chan JM, et al. (February 2020). "Consistent detection of 2019 novel coronavirus in saliva". Clinical Infectious Diseases. Oxford University Press. doi:10.1093/cid/ciaa149. PMC 7108139. PMID 32047895.
  66. ^ "COVID-19 and Our Communities – ACON – We are a New South Wales based health promotion organisation specialising in HIV prevention, HIV support and lesbian, gay, bisexual, transgender and intersex (LGBTI) health". Acon.org.au. Retrieved 29 April 2020.
  67. ^ "Sex and Coronavirus Disease 2019 (COVID-19)" (PDF). nyc.gov. 27 March 2020. Retrieved 29 April 2020.
  68. ^ Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J (2012). "Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review". PLOS ONE. 7 (4): e35797. Bibcode:2012PLoSO...735797T. doi:10.1371/journal.pone.0035797. PMC 3338532. PMID 22563403.
  69. ^ "Novel Coronavirus - Information for Clinicians" (PDF). Australian Government Dept of Health.
  70. ^ "Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): increased transmission beyond China—fourth update" (PDF). European Centre for Disease Prevention and Control. 14 February 2020. Retrieved 8 March 2020.
  71. ^ a b Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (April 2020). "The proximal origin of SARS-CoV-2". Nature Medicine. 26 (4): 450–452. doi:10.1038/s41591-020-0820-9. PMC 7095063. PMID 32284615.
  72. ^ Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. (February 2020). "A Novel Coronavirus from Patients with Pneumonia in China, 2019". The New England Journal of Medicine. 382 (8): 727–733. doi:10.1056/NEJMoa2001017. PMC 7092803. PMID 31978945.
  73. ^ Cyranoski D (March 2020). "Mystery deepens over animal source of coronavirus". Nature. 579 (7797): 18–19. Bibcode:2020Natur.579...18C. doi:10.1038/d41586-020-00548-w. PMID 32127703.
  74. ^ Verdecchia, Paolo; Cavallini, Claudio; Spanevello, Antonio; Angeli, Fabio (12 April 2020). "The pivotal link between ACE2 deficiency and SARS-CoV-2 infection". European Journal of Internal Medicine. doi:10.1016/j.ejim.2020.04.037. PMC 7167588. PMID 32336612.
  75. ^ Letko M, Marzi A, Munster V (April 2020). "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses". Nature Microbiology. 5 (4): 562–569. doi:10.1038/s41564-020-0688-y. PMC 7095430. PMID 32094589.
  76. ^ Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (April 2020). "Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target". Intensive Care Medicine. 46 (4): 586–590. doi:10.1007/s00134-020-05985-9. PMC 7079879. PMID 32125455.
  77. ^ a b Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. (February 2020). "High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa". International Journal of Oral Science. 12 (1): 8. doi:10.1038/s41368-020-0074-x. PMC 7039956. PMID 32094336.
  78. ^ Gurwitz D (March 2020). "Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics". Drug Development Research. doi:10.1002/ddr.21656. PMC 7228359. PMID 32129518.
  79. ^ Li YC, Bai WZ, Hashikawa T (February 2020). "The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients". Journal of Medical Virology. 92 (6): 552–555. doi:10.1002/jmv.25728. PMC 7228394. PMID 32104915.
  80. ^ Baig AM, Khaleeq A, Ali U, Syeda H (April 2020). "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms". ACS Chemical Neuroscience. 11 (7): 995–998. doi:10.1021/acschemneuro.0c00122. PMC 7094171. PMID 32167747.
  81. ^ Gu J, Han B, Wang J (May 2020). "COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission". Gastroenterology. 158 (6): 1518–1519. doi:10.1053/j.gastro.2020.02.054. PMC 7130192. PMID 32142785.
  82. ^ Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H (June 2004). "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis". The Journal of Pathology. 203 (2): 631–7. doi:10.1002/path.1570. PMC 7167720. PMID 15141377.
  83. ^ a b c Zheng YY, Ma YT, Zhang JY, Xie X (May 2020). "COVID-19 and the cardiovascular system". Nature Reviews. Cardiology. 17 (5): 259–260. doi:10.1038/s41569-020-0360-5. PMC 7095524. PMID 32139904.
  84. ^ Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. (February 2020). "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China". JAMA. 323 (11): 1061–1069. doi:10.1001/jama.2020.1585. PMC 7042881. PMID 32031570.
  85. ^ Turner AJ, Hiscox JA, Hooper NM (June 2004). "ACE2: from vasopeptidase to SARS virus receptor". Trends in Pharmacological Sciences. 25 (6): 291–4. doi:10.1016/j.tips.2004.04.001. PMC 7119032. PMID 15165741.
  86. ^ Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. (April 2020). "Incidence of thrombotic complications in critically ill ICU patients with COVID-19". Thrombosis Research. 191: 145–147. doi:10.1016/j.thromres.2020.04.013. PMC 7146714. PMID 32291094.
  87. ^ Cui S, Chen S, Li X, Liu S, Wang F (April 2020). "Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia". Journal of Thrombosis and Haemostasis. doi:10.1111/jth.14830. PMID 32271988.
  88. ^ a b Wadman M (April 2020). "How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes". Science. doi:10.1126/science.abc3208.
  89. ^ Coronavirus: Kidney Damage Caused by COVID-19, Johns Hopkins Medicine, C. John Sperati, updated 14 May 2020.
  90. ^ a b Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S (May 2020). "COVID-19 Autopsies, Oklahoma, USA". American Journal of Clinical Pathology. 153 (6): 725–733. doi:10.1093/ajcp/aqaa062. PMC 7184436. PMID 32275742.
  91. ^ Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (March 2020). "The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality". International Journal of Antimicrobial Agents. 55 (5): 105954. doi:10.1016/j.ijantimicag.2020.105954. PMC 7118634. PMID 32234467.
  92. ^ "CDC Tests for 2019-nCoV". Centers for Disease Control and Prevention (CDC). 5 February 2020. Archived from the original on 14 February 2020. Retrieved 12 February 2020.
  93. ^ "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". World Health Organization (WHO). Archived from the original on 17 March 2020. Retrieved 13 March 2020.
  94. ^ "2019 Novel Coronavirus (2019-nCoV) Situation Summary". Centers for Disease Control and Prevention. 30 January 2020. Archived from the original on 26 January 2020. Retrieved 30 January 2020.
  95. ^ "Real-Time RT-PCR Panel for Detection 2019-nCoV". Centers for Disease Control and Prevention. 29 January 2020. Archived from the original on 30 January 2020. Retrieved 1 February 2020.
  96. ^ "Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe". GlobeNewswire News Room. 30 January 2020. Archived from the original on 31 January 2020. Retrieved 1 February 2020.
  97. ^ Brueck H (30 January 2020). "There's only one way to know if you have the coronavirus, and it involves machines full of spit and mucus". Business Insider. Archived from the original on 1 February 2020. Retrieved 1 February 2020.
  98. ^ "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". Archived from the original on 21 February 2020. Retrieved 26 February 2020.
  99. ^ Cohen J, Normile D (January 2020). "New SARS-like virus in China triggers alarm" (PDF). Science. 367 (6475): 234–235. Bibcode:2020Sci...367..234C. doi:10.1126/science.367.6475.234. PMID 31949058. Archived (PDF) from the original on 11 February 2020. Retrieved 11 February 2020.
  100. ^ "Severe acute respiratory syndrome coronavirus 2 data hub". NCBI. Archived from the original on 21 March 2020. Retrieved 4 March 2020.
  101. ^ Petherick A (April 2020). "Developing antibody tests for SARS-CoV-2". Lancet. 395 (10230): 1101–1102. doi:10.1016/s0140-6736(20)30788-1. PMID 32247384.
  102. ^ Vogel G (March 2020). "New blood tests for antibodies could show true scale of coronavirus pandemic". Science. doi:10.1126/science.abb8028.
  103. ^ Pang J, Wang MX, Ang IY, Tan SH, Lewis RF, Chen JI, et al. (February 2020). "Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review". Journal of Clinical Medicine. 9 (3): 623. doi:10.3390/jcm9030623. PMC 7141113. PMID 32110875.
  104. ^ AFP News Agency (11 April 2020). "How false negatives are complicating COVID-19 testing". Al Jazeera website Retrieved 12 April 2020.
  105. ^ "Coronavirus (COVID-19) Update: FDA Issues first Emergency Use Authorization for Point of Care Diagnostic" (Press release). FDA. 21 March 2020. Archived from the original on 21 March 2020. Retrieved 22 March 2020.
  106. ^ Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. (February 2020). "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)". Military Medical Research. 7 (1): 4. doi:10.1186/s40779-020-0233-6. PMC 7003341. PMID 32029004.
  107. ^ Lee EY, Ng MY, Khong PL (April 2020). "COVID-19 pneumonia: what has CT taught us?". The Lancet. Infectious Diseases. 20 (4): 384–385. doi:10.1016/S1473-3099(20)30134-1. PMC 7128449. PMID 32105641. Archived from the original on 8 March 2020. Retrieved 13 March 2020.
  108. ^ "ICD-10 Version:2019". World Health Organization. 2019. Archived from the original on 31 March 2020. Retrieved 31 March 2020. U07.2—COVID-19, virus not identified—COVID-19 NOS—Use this code when COVID-19 is diagnosed clinically or epidemiologically but laboratory testing is inconclusive or not available. Use additional code, if desired, to identify pneumonia or other manifestations
  109. ^ Hanley B, Lucas SB, Youd E, Swift B, Osborn M (May 2020). "Autopsy in suspected COVID-19 cases". Journal of Clinical Pathology. 73 (5): 239–242. doi:10.1136/jclinpath-2020-206522. PMID 32198191.
  110. ^ Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. (March 2020). "[A pathological report of three COVID-19 cases by minimally invasive autopsies]". Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology (in Chinese). 49 (5): 411–417. doi:10.3760/cma.j.cn112151-20200312-00193. PMID 32172546.
  111. ^ Giani M, Seminati D, Lucchini A, Foti G, Pagni F (May 2020). "Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe". Journal of Thoracic Oncology. 15 (5): e65–e66. doi:10.1016/j.jtho.2020.03.008. PMC 7118681. PMID 32194247.
  112. ^ Lillicrap D (April 2020). "Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia". Journal of Thrombosis and Haemostasis. 18 (4): 786–787. doi:10.1111/jth.14781. PMC 7166410. PMID 32212240.
  113. ^ Mitra A, Dwyre DM, Schivo M, Thompson GR, Cohen SH, Ku N, Graff JP (March 2020). "Leukoerythroblastic reaction in a patient with COVID-19 infection". American Journal of Hematology. doi:10.1002/ajh.25793. PMC 7228283. PMID 32212392.
  114. ^ Wiles S (9 March 2020). "The three phases of Covid-19—and how we can make it manageable". The Spinoff. Archived from the original on 27 March 2020. Retrieved 9 March 2020.
  115. ^ a b c d Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD (March 2020). "How will country-based mitigation measures influence the course of the COVID-19 epidemic?". Lancet. 395 (10228): 931–934. doi:10.1016/S0140-6736(20)30567-5. PMC 7158572. PMID 32164834. A key issue for epidemiologists is helping policy makers decide the main objectives of mitigation—e.g. minimising morbidity and associated mortality, avoiding an epidemic peak that overwhelms health-care services, keeping the effects on the economy within manageable levels, and flattening the epidemic curve to wait for vaccine development and manufacture on scale and antiviral drug therapies.
  116. ^ Barclay E (10 March 2020). "How canceled events and self-quarantines save lives, in one chart". Vox. Archived from the original on 12 March 2020. Retrieved 12 March 2020.
  117. ^ Barclay E, Scott D, Animashaun A (7 April 2020). "The US doesn't just need to flatten the curve. It needs to "raise the line."". Vox. Archived from the original on 7 April 2020.
  118. ^ a b Wiles S (14 March 2020). "After 'Flatten the Curve', we must now 'Stop the Spread'. Here's what that means". The Spinoff. Archived from the original on 26 March 2020. Retrieved 13 March 2020.
  119. ^ a b c d [[Centers for Disease Control and Prevention]|Centers for Disease Control and Prevention]] (3 February 2020). "Coronavirus Disease 2019 (COVID-19): Prevention & Treatment". Archived from the original on 15 December 2019. Retrieved 10 February 2020.
  120. ^ World Health Organization. "Advice for Public". Archived from the original on 26 January 2020. Retrieved 10 February 2020.
  121. ^ "My Hand-Washing Song: Readers Offer Lyrics For A 20-Second Scrub". NPR.org. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
  122. ^ a b "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 17 April 2020.
  123. ^ a b "COVID-19 Treatment Guidelines". www.nih.gov. National Institutes of Health. Retrieved 21 April 2020.
  124. ^ Maragakis LL. "Coronavirus, Social Distancing and Self Quarantine". www.hopkinsmedicine.org. Johns Hopkins University. Archived from the original on 18 March 2020. Retrieved 18 March 2020.
  125. ^ Parker-Pope T (19 March 2020). "Deciding How Much Distance You Should Keep". The New York Times. ISSN 0362-4331. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
  126. ^ a b c d Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (April 2020). "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review". JAMA. doi:10.1001/jama.2020.6019. PMID 32282022.
  127. ^ Systrom K, Krieger M, O'Rourke R, Stein R, Dellaert F, Lerer A (11 April 2020). "Rt Covid-19". rt.live. Retrieved 19 April 2020. Based on Bettencourt LM, Ribeiro RM (May 2008). "Real time bayesian estimation of the epidemic potential of emerging infectious diseases". PLOS ONE. 3 (5): e2185. Bibcode:2008PLoSO...3.2185B. doi:10.1371/journal.pone.0002185. PMC 2366072. PMID 18478118.
  128. ^ Grenfell R, Drew T (17 February 2020). "Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus". Science Alert. Archived from the original on 28 February 2020. Retrieved 26 February 2020.
  129. ^ "When and how to use masks". World Health Organization (WHO). Archived from the original on 7 March 2020. Retrieved 8 March 2020.
  130. ^ Staff (8 April 2020). "Using face masks in the community—Technical Report" (PDF). ECDC.
  131. ^ About Cloth Face Coverings, CDC, Last Reviewed: 22 May 2020.
  132. ^ "For different groups of people: how to choose masks". NHC.gov.cn. National Health Commission of the People's Republic of China. 7 February 2020. Retrieved 22 March 2020. Disposable medical masks: Recommended for: · People in crowded places · Indoor working environment with a relatively dense population · People going to medical institutions · Children in kindergarten and students at school gathering to study and do other activities[permanent dead link]
  133. ^ "Prevention of Coronavirus Disease 2019 (COVID-19)" (PDF). Centre for Health Protection. Archived (PDF) from the original on 21 March 2020. Retrieved 22 March 2020. Wear a surgical mask when taking public transport or staying in crowded places.
  134. ^ Staff (11 April 2020). "Spain officially recommends face mask use". Gazette Life. Retrieved 20 April 2020.
  135. ^ Giuffrida A, Beaumont P (5 April 2020). "Lombardy insists on face masks outside homes to stop Covid-19". The Guardian. ISSN 0261-3077. Retrieved 20 April 2020.
  136. ^ "Russian sanitary watchdog chief supports regions binding people to wear face masks". Tass. 1 May 2020. Retrieved 3 May 2020.
  137. ^ "Coronavirus Disease 2019 (COVID-19)—Prevention & Treatment". Centers for Disease Control and Prevention (CDC). U.S. Department of Health & Human Services. 10 March 2020. Archived from the original on 11 March 2020. Retrieved 11 March 2020.
  138. ^ "WHO-recommended handrub formulations". WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. World Health Organization. 19 March 2009. Retrieved 19 March 2020.
  139. ^ Fisher D, Heymann D (February 2020). "Q&A: The novel coronavirus outbreak causing COVID-19". BMC Medicine. 18 (1): 57. doi:10.1186/s12916-020-01533-w. PMC 7047369. PMID 32106852.
  140. ^ Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. (May 2020). "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province". Chinese Medical Journal. 133 (9): 1025–1031. doi:10.1097/CM9.0000000000000744. PMC 7147277. PMID 32044814.
  141. ^ Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B (March 2020). "Comorbidities and multi-organ injuries in the treatment of COVID-19". Lancet. Elsevier BV. 395 (10228): e52. doi:10.1016/s0140-6736(20)30558-4. PMID 32171074.
  142. ^ Henry BM (April 2020). "COVID-19, ECMO, and lymphopenia: a word of caution". The Lancet. Respiratory Medicine. Elsevier BV. 8 (4): e24. doi:10.1016/s2213-2600(20)30119-3. PMC 7118650. PMID 32178774.
  143. ^ Wang L, Wang Y, Ye D, Liu Q (March 2020). "Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence". International Journal of Antimicrobial Agents: 105948. doi:10.1016/j.ijantimicag.2020.105948. PMC 7156162. PMID 32201353. Archived from the original on 27 March 2020. Retrieved 27 March 2020.
  144. ^ Wang Y, Wang Y, Chen Y, Qin Q (March 2020). "Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures". Journal of Medical Virology. n/a (n/a): 568–576. doi:10.1002/jmv.25748. PMC 7228347. PMID 32134116.
  145. ^ Cheng ZJ, Shan J (April 2020). "2019 Novel coronavirus: where we are and what we know". Infection. 48 (2): 155–163. doi:10.1007/s15010-020-01401-y. PMC 7095345. PMID 32072569.
  146. ^ "Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected". World Health Organization (WHO). Archived from the original on 31 January 2020. Retrieved 13 February 2020.
  147. ^ Farkas J (March 2020). COVID-19—The Internet Book of Critical Care (digital) (Reference manual). USA: EMCrit. Archived from the original on 11 March 2020. Retrieved 13 March 2020.
  148. ^ "COVID19—Resources for Health Care Professionals". Penn Libraries. 11 March 2020. Archived from the original on 14 March 2020. Retrieved 13 March 2020.
  149. ^ Roser M, Ritchie H, Ortiz-Ospina E (4 March 2020). "Coronavirus Disease (COVID-19)". Our World in Data. Archived from the original on 19 March 2020. Retrieved 12 March 2020.
  150. ^ a b c Yanping Z, et al. (The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team) (17 February 2020). "The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)—China, 2020". China CDC Weekly. Chinese Center for Disease Control and Prevention. 2 (8): 113–122. Archived from the original on 19 February 2020. Retrieved 18 March 2020.
  151. ^ Epidemia COVID-19. Aggiornamento nazionale 14 maggio 2020 (PDF) (Report) (in Italian). Rome: Istituto Superiore di Sanità. 15 May 2020. Retrieved 21 May 2020.
  152. ^ Roser M, Ritchie H, Ortiz-Ospina E (6 April 2020). "Coronavirus Disease (COVID-19)". Our World in Data. Retrieved 6 April 2020.
  153. ^ Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. (April 2020). "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review". JAMA Pediatrics. doi:10.1001/jamapediatrics.2020.1467. PMID 32320004.
  154. ^ Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. (April 2020). "SARS-CoV-2 Infection in Children". The New England Journal of Medicine. Massachusetts Medical Society. 382 (17): 1663–1665. doi:10.1056/nejmc2005073. PMC 7121177. PMID 32187458.
  155. ^ Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S (March 2020). "Epidemiology of COVID-19 Among Children in China" (PDF). Pediatrics. 145 (6): e20200702. doi:10.1542/peds.2020-0702. PMID 32179660. Archived (PDF) from the original on 17 March 2020. Retrieved 16 March 2020.
  156. ^ Fang L, Karakiulakis G, Roth M (April 2020). "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?". The Lancet. Respiratory Medicine. 8 (4): e21. doi:10.1016/S0140-6736(20)30311-1. PMC 7118626. PMID 32171062.
  157. ^ "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 2 March 2020. Retrieved 2 March 2020.
  158. ^ Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. (March 2020). "Dysregulation of immune response in patients with COVID-19 in Wuhan, China". Clinical Infectious Diseases. doi:10.1093/cid/ciaa248. PMC 7108125. PMID 32161940.
  159. ^ "WHO Director-General's statement on the advice of the IHR Emergency Committee on Novel Coronavirus". World Health Organization (WHO).
  160. ^ a b Palmieri L, Andrianou X, Barbariol P, Bella A, Bellino S, Benelli E, et al. (3 April 2020). Characteristics of COVID-19 patients dying in Italy Report based on available data on April 2th, 2020 (PDF) (Report). Istituto Superiore di Sanità. Retrieved 3 April 2020.
  161. ^ Wang W, Tang J, Wei F (April 2020). "Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China". Journal of Medical Virology. 92 (4): 441–447. doi:10.1002/jmv.25689. PMC 7167192. PMID 31994742.
  162. ^ "Coronavirus Age, Sex, Demographics (COVID-19)". www.worldometers.info. Archived from the original on 27 February 2020. Retrieved 26 February 2020.
  163. ^ Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. (April 2020). "Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020". MMWR. Morbidity and Mortality Weekly Report. 69 (15): 458–464. doi:10.15585/mmwr.mm6915e3. PMID 32298251.
  164. ^ Ji Y, Ma Z, Peppelenbosch MP, Pan Q (April 2020). "Potential association between COVID-19 mortality and health-care resource availability". The Lancet. Global Health. 8 (4): e480. doi:10.1016/S2214-109X(20)30068-1. PMC 7128131. PMID 32109372.
  165. ^ Cheung E (13 March 2020). "Some recovered Covid-19 patients may have lung damage, doctors say". South China Morning Post. Archived from the original on 15 March 2020. Retrieved 15 March 2020.
  166. ^ Servick K (8 April 2020). "For survivors of severe COVID-19, beating the virus is just the beginning". Science. doi:10.1126/science.abc1486. ISSN 0036-8075.
  167. ^ Berger K (12 March 2020). "The Man Who Saw the Pandemic Coming". Nautilus. Archived from the original on 15 March 2020. Retrieved 16 March 2020.
  168. ^ Heymann DL, Shindo N (February 2020). "COVID-19: what is next for public health?". Lancet. 395 (10224): 542–545. doi:10.1016/S0140-6736(20)30374-3. PMID 32061313.
  169. ^ Wu YC, Chen CS, Chan YJ (March 2020). "The outbreak of COVID-19: An overview". Journal of the Chinese Medical Association. 83 (3): 217–220. doi:10.1097/JCMA.0000000000000270. PMC 7153464. PMID 32134861.
  170. ^ Wang C, Horby PW, Hayden FG, Gao GF (February 2020). "A novel coronavirus outbreak of global health concern". Lancet. 395 (10223): 470–473. doi:10.1016/S0140-6736(20)30185-9. PMC 7135038. PMID 31986257.
  171. ^ Cohen J (January 2020). "Wuhan seafood market may not be source of novel virus spreading globally". Science. doi:10.1126/science.abb0611.
  172. ^ "Novel Coronavirus—China". World Health Organization (WHO). 12 January 2020.
  173. ^ Kessler G (17 April 2020). "Trump's false claim that the WHO said the coronavirus was 'not communicable'". The Washington Post. Archived from the original on 17 April 2020. Retrieved 17 April 2020.
  174. ^ Kuo L (21 January 2020). "China confirms human-to-human transmission of coronavirus". The Guardian. Retrieved 18 April 2020.
  175. ^ "Principles of Epidemiology | Lesson 3—Section 3". www.cdc.gov. 18 February 2019. Archived from the original on 28 February 2020. Retrieved 28 March 2020.
  176. ^ Ritchie H, Roser M (25 March 2020). Chivers T (ed.). "What do we know about the risk of dying from COVID-19?". Our World in Data. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
  177. ^ Lazzerini M, Putoto G (May 2020). "COVID-19 in Italy: momentous decisions and many uncertainties". The Lancet. Global Health. 8 (5): e641–e642. doi:10.1016/S2214-109X(20)30110-8. PMC 7104294. PMID 32199072.
  178. ^ "What do we know about the risk of dying from COVID-19?". Our World in Data. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
  179. ^ a b Hawks L, Woolhandler S, McCormick D (April 2020). "COVID-19 in Prisons and Jails in the United States". JAMA Internal Medicine. doi:10.1001/jamainternmed.2020.1856. PMID 32343355.
  180. ^ Waldstein D (6 May 2020). "To Fight Virus in Prisons, C.D.C. Suggests More Screenings". The New York Times. Retrieved 14 May 2020.
  181. ^ "Total confirmed cases of COVID-19 per million people". Our World in Data. Archived from the original on 19 March 2020. Retrieved 10 April 2020.
  182. ^ "Total confirmed deaths due to COVID-19 per million people". Our World in Data. Archived from the original on 19 March 2020. Retrieved 10 April 2020.
  183. ^ "What do we know about the risk of dying from COVID-19?". Our World in Data. Retrieved 23 April 2020.
  184. ^ "Coronavirus disease 2019 (COVID-19) Situation Report—31" (PDF). 20 February 2020. Retrieved 23 April 2020.
  185. ^ a b "Global Covid-19 Case Fatality Rates". Centre for Evidence-Based Medicine. 17 March 2020. Retrieved 10 April 2020.
  186. ^ Haake D (24 April 2020). "Gangelt – A representative study on the lethality of COVID-19". Medium. Retrieved 27 April 2020.
  187. ^ Vogel G (21 April 2020). "Antibody surveys suggesting vast undercount of coronavirus infections may be unreliable". Science | AAAS. Retrieved 29 April 2020.
  188. ^ Tang, Mei San; Hock, Karl G; Logsdon, Nicole M; Hayes, Jennifer E; Gronowski, Ann M; Anderson, Neil W; Farnsworth, Christopher W (13 May 2020). "Clinical Performance of Two SARS-CoV-2 Serologic Assays". Clinical Chemistry: hvaa120. doi:10.1093/clinchem/hvaa120. ISSN 0009-9147. PMC 7239232. PMID 32402061.
  189. ^ "COVID-19: Data". City of New York.
  190. ^ Modi C (21 April 2020). "How deadly is COVID-19? Data Science offers answers from Italy mortality data". Medium. Retrieved 23 April 2020.
  191. ^ Wu J, McCann A, Katz J, Peltier E (27 April 2020). "36,000 Missing Deaths: Tracking the True Toll of the Coronavirus Crisis". The New York Times. ISSN 0362-4331. Retrieved 27 April 2020.
  192. ^ "The Coronavirus Isn't Just the Flu, Bro". www.bloomberg.com. Retrieved 26 April 2020.
  193. ^ Mole B (24 April 2020). "Experts demolish studies suggesting COVID-19 is no worse than flu". Ars Technica. Retrieved 26 April 2020.
  194. ^ Wilson, Linus (1 May 2020). "SARS-CoV-2, COVID-19, Infection Fatality Rate (IFR) Implied by the Serology, Antibody, Testing in New York City". SSRN 3590771.
  195. ^ a b c Wenham C, Smith J, Morgan R (March 2020). "COVID-19: the gendered impacts of the outbreak". Lancet. 395 (10227): 846–848. doi:10.1016/S0140-6736(20)30526-2. PMC 7124625. PMID 32151325.
  196. ^ Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (February 2020). "[The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]". Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi (in Chamorro). 41 (2): 145–151. doi:10.3760/cma.j.issn.0254-6450.2020.02.003. PMID 32064853.
  197. ^ a b c d Rabin RC (20 March 2020). "In Italy, Coronavirus Takes a Higher Toll on Men". The New York Times. Retrieved 7 April 2020.
  198. ^ "COVID-19 weekly surveillance report". www.euro.who.int. Retrieved 7 April 2020.
  199. ^ a b Gupta AH (3 April 2020). "Does Covid-19 Hit Women and Men Differently? U.S. Isn't Keeping Track". The New York Times. Retrieved 7 April 2020.
  200. ^ "Gender equity in the health workforce: Analysis of 104 countries" (PDF). World Health Organization. Retrieved 7 April 2020.
  201. ^ "Gender and the Coronavirus Outbreak: Think Global Health". Council on Foreign Relations. Retrieved 7 April 2020.
  202. ^ a b Dorn AV, Cooney RE, Sabin ML (April 2020). "COVID-19 exacerbating inequalities in the US". Lancet. 395 (10232): 1243–1244. doi:10.1016/S0140-6736(20)30893-X. PMC 7162639. PMID 32305087.
  203. ^ Adams ML, Katz DL, Grandpre J (April 2020). "Population-Based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States". Emerging Infectious Diseases. 26 (8). doi:10.3201/eid2608.200679. PMID 32324118.
  204. ^ "COVID-19 Presents Significant Risks for American Indian and Alaska Native People". 14 May 2020.
  205. ^ "COVID-19 Presents Significant Risks for American Indian and Alaska Native People". 14 May 2020.
  206. ^ Laurencin CT, McClinton A (April 2020). "The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities". Journal of Racial and Ethnic Health Disparities. 7 (3): 398–402. doi:10.1007/s40615-020-00756-0. PMC 7166096. PMID 32306369.
  207. ^ "2nd U.S. Case Of Wuhan Coronavirus Confirmed". NPR.org. Retrieved 4 April 2020.
  208. ^ McNeil Jr DG (2 February 2020). "Wuhan Coronavirus Looks Increasingly Like a Pandemic, Experts Say". The New York Times. ISSN 0362-4331. Retrieved 4 April 2020.
  209. ^ Griffiths J. "Wuhan coronavirus deaths spike again as outbreak shows no signs of slowing". CNN. Retrieved 4 April 2020.
  210. ^ Jiang S, Xia S, Ying T, Lu L (May 2020). "A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome". Cellular & Molecular Immunology. 17 (5): 554. doi:10.1038/s41423-020-0372-4. PMC 7091741. PMID 32024976.
  211. ^ Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. (February 2020). "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster". Lancet. 395 (10223): 514–523. doi:10.1016/S0140-6736(20)30154-9. PMC 7159286. PMID 31986261.
  212. ^ Shablovsky S (22 September 2017). "The legacy of the Spanish flu". Science. 357 (6357): 1245. Bibcode:2017Sci...357.1245S. doi:10.1126/science.aao4093. ISSN 0036-8075.
  213. ^ "Stop the coronavirus stigma now". Nature. 7 April 2020. p. 165. doi:10.1038/d41586-020-01009-0. Retrieved 16 April 2020.
  214. ^ "Novel Coronavirus (2019-nCoV) SITUATION REPORT—1" (PDF). World Health Organization (WHO). 21 January 2020.
  215. ^ "Novel Coronavirus(2019-nCoV) Situation Report—10" (PDF). World Health Organization (WHO). 30 January 2020.
  216. ^ "Novel coronavirus named 'Covid-19': WHO". TODAYonline. Archived from the original on 21 March 2020. Retrieved 11 February 2020.
  217. ^ "The coronavirus spreads racism against—and among—ethnic Chinese". The Economist. 17 February 2020. Archived from the original on 17 February 2020. Retrieved 17 February 2020.
  218. ^ "World Health Organization Best Practices for the Naming of New Human Infectious Diseases" (PDF). World Health Organization (WHO). May 2015.
  219. ^ a b "Naming the coronavirus disease (COVID-19) and the virus that causes it". World Health Organization (WHO). Archived from the original on 28 February 2020. Retrieved 13 March 2020.
  220. ^ "Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK—eighth update" (PDF). ecdc. Archived (PDF) from the original on 14 March 2020. Retrieved 19 April 2020.
  221. ^ "China coronavirus: Misinformation spreads online about origin and scale". BBC News. 30 January 2020. Archived from the original on 4 February 2020. Retrieved 10 February 2020.
  222. ^ Taylor J (31 January 2020). "Bat soup, dodgy cures and 'diseasology': the spread of coronavirus misinformation". The Guardian. Archived from the original on 2 February 2020. Retrieved 3 February 2020.
  223. ^ "Here's A Running List Of Disinformation Spreading About The Coronavirus". Buzzfeed News. Archived from the original on 6 February 2020. Retrieved 8 February 2020.
  224. ^ Metzler B, Siostrzonek P, Binder RK, Bauer A, Reinstadler SJ (April 2020). "Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage". European Heart Journal. 41 (19): 1852–1853. doi:10.1093/eurheartj/ehaa314. PMC 7184486. PMID 32297932.
  225. ^ Garcia S, Albaghdadi MS, Meraj PM, Schmidt C, Garberich R, Jaffer FA, et al. (April 2020). "Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic". Journal of the American College of Cardiology. 75 (22): 2871–2872. doi:10.1016/j.jacc.2020.04.011. PMC 7151384. PMID 32283124.
  226. ^ a b 'Where are all our patients?': Covid phobia is keeping people with serious heart symptoms away from ERs, Stat News, Usha Lee McFarling, 23 April 2020.
  227. ^ Kolata G (25 April 2020). "Amid the Coronavirus Crisis, Heart and Stroke Patients Go Missing". The New York Times. Retrieved 14 May 2020.
  228. ^ "Coronavirus: Belgian cat infected by owner". Brusselstimes.com. 27 March 2020. Retrieved 12 April 2020.
  229. ^ Goldstein J (6 April 2020). "Bronx Zoo Tiger Is Sick With the Coronavirus". The New York Times. Retrieved 9 April 2020.
  230. ^ "Coronavirus hits Netherlands farm animals as minks test positive for virus". Fox News. 26 April 2020. Retrieved 27 April 2020.
  231. ^ Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, et al. (April 2020). "Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2". Science. 368 (6494): 1016–1020. doi:10.1126/science.abb7015. PMC 7164390. PMID 32269068.
  232. ^ Chan JF, Zhang AJ, Yuan S, et al. (March 2020). "Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility" (PDF). Clinical Infectious Diseases. doi:10.1093/cid/ciaa325. ISSN 1058-4838. PMC 7184405. PMID 32215622.
  233. ^ a b c Li G, De Clercq E (March 2020). "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)". Nature Reviews. Drug Discovery. 19 (3): 149–150. doi:10.1038/d41573-020-00016-0. PMID 32127666.
  234. ^ Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W (March 2020). "COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics". Human Vaccines & Immunotherapeutics: 1–7. doi:10.1080/21645515.2020.1735227. PMC 7103671. PMID 32186952.
  235. ^ Zhang L, Liu Y (May 2020). "Potential interventions for novel coronavirus in China: A systematic review". Journal of Medical Virology. 92 (5): 479–490. doi:10.1002/jmv.25707. PMC 7166986. PMID 32052466.
  236. ^ a b Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. Retrieved 27 March 2020.
  237. ^ "Citing safety concerns, the W.H.O. paused tests of a drug Trump said he had taken". The New York Times. 26 May 2020.
  238. ^ "France bans use of hydroxychloroquine, drug touted by Trump, in coronavirus patients". CBS News. 27 May 2020.
  239. ^ Bradley-Ridout G, Fuller K, Gray M, Nekolaichuk E (9 April 2020). "Navigating the COVID-19 Evidence Landscape". University of Toronto Libraries - Gerstein Science Information Centre.
  240. ^ Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (March 2020). "Features, Evaluation and Treatment Coronavirus (COVID-19)". StatPearls [Internet]. StatPearls. PMID 32150360. Bookshelf ID: NBK554776.
  241. ^ Chen WH, Strych U, Hotez PJ, Bottazzi ME (March 2020). "The SARS-CoV-2 Vaccine Pipeline: an Overview". Current Tropical Medicine Reports: 1–4. doi:10.1007/s40475-020-00201-6. PMC 7094941. PMID 32219057.
  242. ^ Roberts M (17 March 2020). "Coronavirus: US volunteers test first vaccine". BBC News Online. Archived from the original on 17 March 2020. Retrieved 17 March 2020.
  243. ^ Peeples L (April 2020). "News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine". Proceedings of the National Academy of Sciences of the United States of America. Proceedings of the National Academy of Sciences. 117 (15): 8218–8221. doi:10.1073/pnas.2005456117. PMC 7165470. PMID 32229574.
  244. ^ a b c "COVID-19 treatment and vaccine tracker" (PDF). Milken Institute. 21 April 2020. Retrieved 21 April 2020. Lay summary.
  245. ^ a b c d Koch S, Pong W (13 March 2020). "First up for COVID-19: nearly 30 clinical readouts before end of April". BioCentury Inc. Retrieved 1 April 2020.
  246. ^ COVID-19 Clinical Research Coalition (April 2020). "Global coalition to accelerate COVID-19 clinical research in resource-limited settings". Lancet. 395 (10233): 1322–1325. doi:10.1016/s0140-6736(20)30798-4. PMID 32247324.
  247. ^ Maguire BJ, Guérin PJ (2 April 2020). "A living systematic review protocol for COVID-19 clinical trial registrations". Wellcome Open Research. 5: 60. doi:10.12688/wellcomeopenres.15821.1. PMC 7141164. PMID 32292826.
  248. ^ "UN health chief announces global 'solidarity trial' to jumpstart search for COVID-19 treatment". UN News. 18 March 2020. Archived from the original on 23 March 2020. Retrieved 23 March 2020.
  249. ^ Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, Hsueh PR (April 2020). "Arguments in favour of remdesivir for treating SARS-CoV-2 infections". International Journal of Antimicrobial Agents. 55 (4): 105933. doi:10.1016/j.ijantimicag.2020.105933. PMC 7135364. PMID 32147516.
  250. ^ Feuerstein A, Garde D, Robbins R (16 April 2020). "Gilead data suggests coronavirus patients are responding to treatment". STAT. Retrieved 16 April 2020.
  251. ^ Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. (April 2020). "Compassionate Use of Remdesivir for Patients with Severe Covid-19". The New England Journal of Medicine. doi:10.1056/NEJMoa2007016. PMC 7169476. PMID 32275812.
  252. ^ a b Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. (March 2020). "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Cell Research. 30 (3): 269–271. doi:10.1038/s41422-020-0282-0. PMC 7054408. PMID 32020029.
  253. ^ Beeching NJ, Fletcher TE, Fowler R (2020). "BMJ Best Practices: COVID-19" (PDF). BMJ. Archived (PDF) from the original on 22 February 2020. Retrieved 11 March 2020.
  254. ^ Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (May 2020). "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19". The New England Journal of Medicine. 382 (19): 1787–1799. doi:10.1056/NEJMoa2001282. PMC 7121492. PMID 32187464.
  255. ^ Seley-Radtke K (3 April 2020). "Professor of Chemistry and Biochemistry and President-Elect of the International Society for Antiviral Research, University of Maryland, Baltimore County". The Conversation. Retrieved 5 April 2020.
  256. ^ Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N (March 2020). "No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection". Medecine et Maladies Infectieuses (in French). 50 (4): S0399077X20300858. doi:10.1016/j.medmal.2020.03.006. PMC 7195369. PMID 32240719.
  257. ^ Cha, Ariana Eunjung; health, closeAriana Eunjung ChaNational reporterEmailEmailBioBioFollowFollowLaurie McGinley closeLaurie McGinleyReporter covering; medicineEmailEmailBioBioFollowFollow. "Antimalarial drug touted by President Trump is linked to increased risk of death in coronavirus patients, study says". Washington Post. Retrieved 27 May 2020.
  258. ^ Mehra, Mandeep R.; Desai, Sapan S.; Ruschitzka, Frank; Patel, Amit N. (22 May 2020). "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis". The Lancet. 0. doi:10.1016/S0140-6736(20)31180-6. ISSN 0140-6736. PMC 7255293. PMID 32450107.
  259. ^ Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. (March 2020). "In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)". Clinical Infectious Diseases. doi:10.1093/cid/ciaa237. PMC 7108130. PMID 32150618.
  260. ^ Liu R, Miller J (3 March 2020). "China approves use of Roche drug in battle against coronavirus complications". Reuters. Archived from the original on 12 March 2020. Retrieved 14 March 2020.
  261. ^ "Effective Treatment of Severe COVID-19 Patients with Tocilizumab". ChinaXiv.org. 5 March 2020. doi:10.12074/202003.00026 (inactive 1 June 2020). Archived from the original on 19 March 2020. Retrieved 14 March 2020. Cite journal requires |journal= (help)
  262. ^ Ovadia D, Agenzia Z. "COVID-19—Italy launches an independent trial on tocilizumab". Univadis from Medscape. Aptus Health. Retrieved 22 April 2020.
  263. ^ "Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19)". www.clinicaltrials.gov. National Library of Medicine. Retrieved 22 April 2020.
  264. ^ "How doctors can potentially significantly reduce the number of deaths from Covid-19". Vox. 12 March 2020. Archived from the original on 19 March 2020. Retrieved 14 March 2020.
  265. ^ Ruan Q, Yang K, Wang W, Jiang L, Song J (March 2020). "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China". Intensive Care Medicine. 46 (5): 846–848. doi:10.1007/s00134-020-05991-x. PMC 7080116. PMID 32125452.
  266. ^ Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (March 2020). "COVID-19: consider cytokine storm syndromes and immunosuppression". Lancet. 395 (10229): 1033–1034. doi:10.1016/S0140-6736(20)30628-0. PMID 32192578.
  267. ^ Slater H (26 March 2020). "FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia". www.cancernetwork.com. Cancer Network. Retrieved 22 April 2020.
  268. ^ Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, et al. (2017). "Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)". Blood. 130 (Supplement 1): 1547. doi:10.1182/blood.V130.Suppl_1.1547.1547 (inactive 16 May 2020).
  269. ^ Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. (February 2019). "GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts". Blood. 133 (7): 697–709. doi:10.1182/blood-2018-10-881722. PMC 6376281. PMID 30463995.
  270. ^ "Northwell Health Initiates Clinical Trials of 2 COVID-19 Drugs". 21 March 2020. Archived from the original on 23 March 2020. Retrieved 23 March 2020.
  271. ^ a b c d Casadevall A, Pirofski LA (April 2020). "The convalescent sera option for containing COVID-19". The Journal of Clinical Investigation. 130 (4): 1545–1548. doi:10.1172/JCI138003. PMC 7108922. PMID 32167489.
  272. ^ a b Ho, Mitchell (2020). "Perspectives on the development of neutralizing antibodies against SARS-CoV-2". Antibody Therapeutics. doi:10.1093/abt/tbaa009.
  273. ^ Pearce K (13 March 2020). "Antibodies from COVID-19 survivors could be used to treat patients, protect those at risk: Infusions of antibody-laden blood have been used with reported success in prior outbreaks, including the SARS epidemic and the 1918 flu pandemic". The Hub at Johns Hopkins University. Archived from the original on 14 March 2020. Retrieved 14 March 2020.

External links

Health agencies

Directories

Medical journals

Classification

Notes

This article is a direct transclusion of the Wikipedia article and therefore may not meet the same editing standards as LIMSwiki.